- Home
- CRSP vs SLG Comparison
CRSP vs SLG Comparison
Compare CRSP & SLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SLG
- Stock Information
- Founded
- CRSP 2013
- SLG 1980
- Country
- CRSP Switzerland
- SLG United States
- Employees
- CRSP N/A
- SLG N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SLG Real Estate Investment Trusts
- Sector
- CRSP Health Care
- SLG Real Estate
- Exchange
- CRSP Nasdaq
- SLG Nasdaq
- Market Cap
- CRSP 4.0B
- SLG 4.5B
- IPO Year
- CRSP 2016
- SLG 1997
- Fundamental
- Price
- CRSP $47.25
- SLG $75.63
- Analyst Decision
- CRSP Buy
- SLG Hold
- Analyst Count
- CRSP 19
- SLG 14
- Target Price
- CRSP $73.69
- SLG $65.21
- AVG Volume (30 Days)
- CRSP 1.8M
- SLG 701.1K
- Earning Date
- CRSP 11-05-2024
- SLG 10-16-2024
- Dividend Yield
- CRSP N/A
- SLG 3.97%
- EPS Growth
- CRSP N/A
- SLG N/A
- EPS
- CRSP N/A
- SLG N/A
- Revenue
- CRSP $202,829,000.00
- SLG $920,135,000.00
- Revenue This Year
- CRSP N/A
- SLG N/A
- Revenue Next Year
- CRSP $526.27
- SLG $5.27
- P/E Ratio
- CRSP N/A
- SLG N/A
- Revenue Growth
- CRSP 19.31
- SLG N/A
- 52 Week Low
- CRSP $43.42
- SLG $32.78
- 52 Week High
- CRSP $91.10
- SLG $82.81
- Technical
- Relative Strength Index (RSI)
- CRSP 44.94
- SLG 49.62
- Support Level
- CRSP $50.60
- SLG $75.77
- Resistance Level
- CRSP $59.07
- SLG $82.81
- Average True Range (ATR)
- CRSP 2.84
- SLG 2.62
- MACD
- CRSP -0.35
- SLG -0.58
- Stochastic Oscillator
- CRSP 7.48
- SLG 21.87
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.